Table 2.
Altered mimic peptides fail to induce EAE
|
Immunizing Aga) |
No. EAE |
Mean group score ± SEM |
Mean day of onset ± SEM |
|---|---|---|---|
|
OVA |
0/5 |
0.0 ± 0.0 |
0.0 ± 0.0 |
|
PLP |
5/5 |
3.4 ± 0.5 |
13.8 ± 1.3 |
|
HI |
0/5 |
0.0 ± 0.0 |
0.0 ± 0.0 |
|
HI–P |
0/5 |
0.0 ± 0.0 |
0.0 ± 0.0 |
|
MHV |
0/5 |
0.0 ± 0.0 |
0.0 ± 0.0 |
|
MHV+P |
0/5 |
0.0 ± 0.0 |
0.0 ± 0.0 |
a) Separate groups of mice were immunized s.c. on day 0 with 100 µg of either “self” myelin peptide PLP139–151 (PLP), viral mimic peptides MHV3821–3832 (MHV) or MHV3821–3832+P (MHV+P), bacterial mimic peptides HI574–586 (HI) or HI574–586–P (HI–P), or a control non‐self, non‐mimic peptide OVA323–339 (OVA) and observed for signs of clinical EAE. Results represent the number of mice that developed EAE, the mean group clinical score ± SEM, and the mean day of onset ± SEM.